10-year kinase inhibitor research in a nutshell
Our white paper (free download) describes trends over a decade of small molecule Protein Kinase Inhibitor (PKI) research by mining thousands of American Society for Cancer Research (AACR) abstracts covering the period of 2004-2013. You can access relevant information relating to drug discovery and research that could be important for you!
The paper describes research on:
- 26 approved PKIs and other DrugBank drugs
- over 300 PKI’s of over 90 companies and institutes with the top-4 companies being Pfizer, Novartis, AstraZeneca and GlaxoSmithKline
- up to 69 kinase targets with a top-4 of EGFR, HER, PDGFR and VEGFR covering more than 50% of targeted kinase
A sample figure below shows that the number of kinase small molecule inhibitor drugs described each year has tripled from 40 to 120:
Download the Whitepaper: